MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

Начало・Списък с акции・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

20.22 7.61

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

18.81

Максимум

20.68

Ключови измерители
By Trading Economics
Приходи	-14M -50M
Продажби	12M 128M
Марж на печалбата	-39.506
Служители	1,784
EBITDA	-17M -48M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+85.91% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-194M 2B
Предишно отваряне	12.61
Предишно затваряне	20.22

Настроения в новините

By Acuity

43%

57%

146 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

28.13 / 31.12 Подкрепа & съпротива

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.04.2026 г., 22:56 ч. UTC

Значими събития в новините

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1.04.2026 г., 20:50 ч. UTC

Придобивния, сливания и поглъщания

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1.04.2026 г., 23:55 ч. UTC

Пазарно говорене

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1.04.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1.04.2026 г., 23:23 ч. UTC

Значими събития в новините

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1.04.2026 г., 23:07 ч. UTC

Печалби

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1.04.2026 г., 23:02 ч. UTC

Значими събития в новините

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1.04.2026 г., 23:00 ч. UTC

Значими събития в новините

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1.04.2026 г., 23:00 ч. UTC

Значими събития в новините

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1.04.2026 г., 23:00 ч. UTC

Значими събития в новините

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1.04.2026 г., 22:39 ч. UTC

Печалби

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1.04.2026 г., 22:08 ч. UTC

Пазарно говорене

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1.04.2026 г., 21:56 ч. UTC

Придобивния, сливания и поглъщания

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1.04.2026 г., 21:31 ч. UTC

Значими събития в новините

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

1.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

1.04.2026 г., 20:38 ч. UTC

Печалби

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1.04.2026 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1.04.2026 г., 20:16 ч. UTC

Придобивния, сливания и поглъщания

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1.04.2026 г., 20:16 ч. UTC

Придобивния, сливания и поглъщания

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1.04.2026 г., 20:13 ч. UTC

Придобивния, сливания и поглъщания

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1.04.2026 г., 20:07 ч. UTC

Пазарно говорене

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1.04.2026 г., 20:07 ч. UTC

Придобивния, сливания и поглъщания

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

85.91% нагоре

12-месечна прогноза

Среден 34.97 USD 85.91%

Висок 47 USD

Нисък 21.8 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Zai Lab Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

146 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.